To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

April 30, 2018

Today's Rundown

Featured Story

AbbVie halts trial of Stemcentrx-sourced ADC for cancer

AbbVie has terminated an early-stage trial of an antibody-drug conjugate (ADC) for solid tumors, one of the candidates acquired as part of its $9.8 billion takeover of Stemcentrx in 2016.

Top Stories

Lilly hires Leena Gandhi as new look I-O team takes shape

Eli Lilly has appointed Leena Gandhi, M.D., Ph.D., to lead immuno-oncology medical development. The thoracic oncologist will head up a team tasked with overseeing the advance of Lilly’s portfolio of immuno-oncology prospects.

After months of mounting pressure amid lurid allegations, OrbiMed’s Isaly steps down

Sam Isaly has now finally left OrbiMed, the venture capital firm he founded, amid allegations of sexual impropriety.

[Sponsored] Getting to True Agile IRT: 5 Questions to Ask Your IRT Vendor

Download the article and better understand the five questions that will help you separate myth from reality when it comes to Agile IRT.

Kiniksa and Scholar Rock gun for $175M IPOs as 2 other biotechs struggle

It was something of an up-and-down week for IPOs: Two biotechs, Alzheimer’s-focused Alzheon and brittle bone drug company Mereo BioPharma, pulled their collective $161 million Nasdaq attempts. But the week ended with better news for two other biotechs.

Proniras launches with BARDA funding to pit migraine drug against nerve agents

Accelerator Life Science Partners launched a spinoff company to develop an investigational migraine treatment into a therapy for a variety of seizure disorders and landed an $89.5 million federal contract to explore the drug’s use as a medical countermeasure against the effects of nerve agents.

Just shy of phase 3, Alzheon calls off $81M IPO

Alzheon had planned to advance its once-failed Alzheimer's drug with the IPO funds, but now its phase 3 ambitions remain on hold.

Crescendo raises $70M to trial bispecific T-cell engager

Crescendo Biologics has raised $70 million (€57 million) to take its lead bispecific T-cell engager into the clinic. The financing equips Crescendo to show whether its vision for dialing up T-cell activity in the tumor microenvironment translates into humans.

Synthorx reels in $63M to push synthetic cytokines into the clinic

The funding will advance its pipelines of synthetic cytokines, which are designed to improve the efficacy of immuno-oncology treatments without the negative side effects that sometimes come with native cytokines.

[Sponsored] Australia the not-so-secret destination for pharma and biotech clinical trials

Supported by generous tax breaks and backed up by strong clinical research and healthcare organizations, Australia has become the not-so-secret destination for both small and large pharmaceutical and biotech companies looking to conduct early stage clinical trials.

Jazz grabs Spark’s priority review voucher for $110M

Spark Therapeutics agreed to sell its priority review voucher, good for four months off an FDA decision date for any product, to Jazz Pharmaceuticals for $110 million—providing Spark a nice bonus on top of the recent approval for what’s been described as the world’s most expensive drug, Luxturna.

Roivant’s Datavant raises $41M, buys data de-identification firm UPK

Datavant has raised $40.5 million and acquired Universal Patient Key (UPK). The takeover gives the Roivant startup control of HIPAA-compliant "de-identification" technology to support its drive to link up sources of health data.

Enrollment Showcase

Online Graduate Programs Designed for Your Career

Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more.

Resources

[Whitepaper] Five Tracking Spreadsheets it’s Time for Regulatory to Retire

Find out how to eliminate regulatory’s tracking spreadsheets for good.

[Whitepaper] Regulatory Transformation at UCB

UCB took a more holistic approach to managing regulatory processes. Read how their efforts are paying off.

[Whitepaper] Risk-based Approach to Change Management of GxP Systems

Learn how to reduce change management burden, keep systems current, and maintain compliance by applying a risk-based approach to change management of GxP systems.

[Whitepaper] Compliance Certificate and Training for Life Sciences Professionals

4-day interactive educational program trusted by multi-national companies as part of their compliance training for employees. Explore legal, regulatory and ethical issues faced by pharmaceutical, biotech and medical device manufacturers operating globally. Visit event homepage for session topics.

[Whitepaper] MSL Outlook: What is the Future of Field Medical Affairs?

Learn how leading companies, from the world’s top pharma to emerging biotechs, are empowering their medical affairs teams.

[Whitepaper] Leveraging Scientific Insights for Better Healthcare Engagement

To deliver value to key opinion leaders, medical affairs needs to tailor their engagement with deeper analytics and insights.

[Whitepaper] The Future of Life Sciences Events Management

Explore a new model for events management, and learn how to deliver more value.

[Whitepaper] Not Like Everyone Else: Unique Challenges for Small Biopharma Companies

Small biopharma companies are conducting almost 50% of the clinical trials in the US today, yet they face unique challenges that large pharma do not. In this paper, we explore some of those challenges, and solutions that can reduce the pressure on small biopharma teams and timelines.

[Whitepaper] For Fixed-Dose Combination Manufacturing, Confidence Matters

Why does confidence matter when outsourcing Fixed-Dose Combination products? Download Halo Pharma’s white paper on the importance of product design, technology, and analyticals tools for FDC.

[Whitepaper] 2018 Life Sciences Trends

What are the biggest trends in life sciences this year?

[Video] So Many Choices: What’s the Right Biomanufacturing Strategy for Me?

Patheon's Stephen Lam reviews the formidable challenges and decisions facing biopharma manufacturing executives. Watch as he shares unique insights and perspectives and demonstrates how there is really no one-size-fits-all solution in biomanufacturing, regardless of company size.

[Meeting] AACR Annual Meeting 2018

How do you get your oncology therapy to the clinic? The path isn’t always clear. In vitro, ex vivo, xenograft, syngeneic, PDX, humanized models, immunology considerations, safety regulations – which do you need to plan for and when?

[Whitepaper] Digitizing the Global Life Sciences Supply Chain: The Critical Role of Digital Transaction Management

Life science companies are experiencing a significant transformation in how they bring new products to market.

[Whitepaper] Choosing the Right Solution: Improving the Site Feasibility Process

Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals.

[Whitepaper] How Do Sponsors Ensure Quality in Global Clinical Trials?

Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives.

[Webinar] Validating a 7 Day Membrane Filtration Sterility Test using Celsis®

Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols.

[Infographic] Evolution of Flexible Commercial Biologics Manufacturing

Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility.

[eBook] Developing Site-specifically Modified ADCs: Using a Chemoenzymatic Approach

Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology.

[Article] Optimizing titer and use of a specific enzyme for generating a fully processed antibody

Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing.

[Webinar] Within-Subject Clinical Trials: Intro to New Methods & Stat. Models

In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods.

Events

.